We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
+2.67%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$342M
AUM Growth
+$131M
(+62%)
Cap. Flow
+$283M
Cap. Flow
% of AUM
82.7%
Top 10 Holdings %
Top 10 Hldgs %
60.71%
Holding
50
New
9
Increased
24
Reduced
4
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pacira BioSciences
PCRX
|
+$32.5M |
| 2 |
MeiraGTx Holdings
MGTX
|
+$16.7M |
| 3 |
Kura Oncology
KURA
|
+$15.9M |
| 4 |
Humana
HUM
|
+$15.7M |
| 5 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$14.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prothena Corp
PRTA
|
+$21.1M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$8.84M |
| 3 |
Arcturus Therapeutics
ARCT
|
+$6.11M |
| 4 |
Alkermes
ALKS
|
+$5.11M |
| 5 |
Cue Biopharma
CUE
|
+$4.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pacira BioSciences
PCRX
$1.02B
| $35.2M | 10.29% |
877,586
+786,463
| +863% | +$32.5M |
|
|
2
MeiraGTx Holdings
MGTX
$1.09B
| $27.4M | 8.02% |
4,078,804
+2,589,887
| +174% | +$16.7M |
|
|
3
Humana
HUM
$46.7B
| $24.6M | 7.21% |
55,100
+31,100
| +130% | +$15.7M |
|
4
Oric Pharmaceuticals
ORIC
$1.25B
| $21.4M | 6.27% |
2,761,468
+1,216,468
| +79% | +$6.91M |
|
5
BioCryst Pharmaceuticals
BCRX
$2.37B
| $17.6M | 5.15% |
2,500,000
+1,425,407
| +133% | +$11.4M |
|
6
Mirum Pharmaceuticals
MIRM
$6.89B
| $17.5M | 5.11% |
675,000
+107,174
| +19% | +$2.85M |
|
|
LKFT
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
| $17M | 4.97% |
417,500
+42,000
| +11% | +$1.71M |
|
8
AbCellera Biologics
ABCL
$1.62B
| $16.5M | 4.82% |
2,550,000
+1,796,472
| +238% | +$12.3M |
|
9
Neurocrine Biosciences
NBIX
$17.7B
| $16M | 4.69% |
170,000
+90,000
| +113% | +$8.79M |
|
|
10
Kura Oncology
KURA
$922M
| $14.2M | 4.16% |
+1,343,359
| New | +$15.9M |
|
11
Centene
CNC
$31.3B
| $13.2M | 3.86% |
195,670
+34,266
| +21% | +$2.29M |
|
12
ADC Therapeutics
ADCT
$146M
| $12M | 3.51% |
5,583,900
+2,326,540
| +71% | +$5.23M |
|
|
KZR
13
DELISTED
Kezar Life Sciences
KZR
| $11.4M | 3.34% |
465,192
+145,192
| +45% | +$3.78M |
|
14
QuidelOrtho
QDEL
$1.09B
| $9.15M | 2.68% |
110,468
+62,113
| +128% | +$5.44M |
|
|
15
Prothena Corp
PRTA
$458M
| $8.19M | 2.4% |
120,000
-327,092
| -73% | -$21.1M |
|
|
NSTG
16
DELISTED
NanoString Technologies, Inc.
NSTG
| $8.1M | 2.37% |
+2,000,000
| New | +$14.8M |
|
17
Option Care Health
OPCH
$3.4B
| $7.66M | 2.24% |
235,780
+80,880
| +52% | +$2.44M |
|
18
UnitedHealth
UNH
$382B
| $7.21M | 2.11% |
15,000
+4,065
| +37% | +$1.99M |
|
|
NARI
19
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $6.9M | 2.02% |
118,684
+56,603
| +91% | +$3.57M |
|
20
Shattuck Labs
STTK
$710M
| $6.58M | 1.93% |
2,109,620
+87,952
| +4% | +$255K |
|
|
LBPH
21
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $5.39M | 1.58% |
734,897
-165,703
| -18% | -$1.25M |
|
22
Medtronic
MDT
$107B
| $5.29M | 1.55% |
+60,000
| New | +$5.17M |
|
|
23
Alkermes
ALKS
$8.82B
| $4.62M | 1.35% |
147,554
-168,611
| -53% | -$5.11M |
|
|
LENZ
24
LENZ Therapeutics
LENZ
$172M
| $4.42M | 1.29% |
242,857
+117,619
| +94% | +$2.35M |
|
25
Erasca
ERAS
$6.63B
| $4.3M | 1.26% |
1,557,370
+378,280
| +32% | +$1.08M |
|
Similar funds
PL
BFC
DCM
SAM
CBB
AIG
FFWA
CIP
Prosight Management's Q2 2023 Portfolio in Review
As of Q2 2023, Prosight Management held 50 positions worth $342M, up 62% from $211M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Prosight Management deployed $283M of net new capital in Q2 2023, opening 9 new positions and adding to 24 existing holdings. Its largest new stake was Kura Oncology: 1,343,359 shares worth $14.2M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.
On the sell side, the largest reduction was Prothena Corp, an estimated $21.1M trimmed.
- Prosight Management's largest Q2 2023 buy was Kura Oncology: 1,343,359 shares worth $14.2M.
- Prosight Management added most to Pacira BioSciences in Q2 2023, an estimated $32.5M increase.
- Prosight Management's biggest Q2 2023 reduction was Prothena Corp, cutting an estimated $21.1M.
- Prosight Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023, selling an estimated $8.84M.
- Prosight Management's ten largest holdings make up 61% of its $342M portfolio in Q2 2023.
- Prosight Management opened 9 new positions and closed 13 in Q2 2023.
- Prosight Management's portfolio value rose 62% quarter-over-quarter to $342M.
Based on Prosight Management's 13F filing for Q2 2023, filed 14 Aug 2023.